1) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 2) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
1424
Matsumoto M, Nagaki K, Kitamura H, Kuramitsu S, Nagasawa S, Seya T.
Probing the C4-binding site on C1s with monoclonal antibodies. Evidence for a C4/C4b-binding site on the gamma-domainJ Immunol
1989
142(8):2743-50
PubMed ID: 2522968
1423
Matsumoto M, Nagaki K.
Functional analysis of activated C1s, a subcomponent of the first component of human complement, by monoclonal antibodiesJ Immunol
1986
137(9):2907-12
PubMed ID: 2428878